biotech
Workflow 01
Biomarker Strategy
Identify, prioritize, and contextualize biomarkers based on disease biology, clinical relevance, competitive landscape, assay feasibility, and development value.
Includes
- Biomarker prioritization
- Disease-specific biomarker landscape
- Mechanism-of-action alignment
- Patient segmentation and translational rationale
Example outputs
- Ranked biomarker list
- Evidence summary
- Biological rationale
- Strategy recommendation
clinical_notes
Workflow 02
Biomarker-Based Clinical Trial Planning
Support translational and clinical teams in planning biomarker-informed development strategies across patient enrichment, evidence, feasibility, and competitive dynamics.
Includes
- Patient enrichment rationale
- Biomarker-informed inclusion and exclusion
- Trial landscape and competitor benchmarking
- Recruitment and prevalence feasibility
Example outputs
- Trial planning summary
- Competitor benchmark
- Assay and testing considerations
- Development-stage recommendation
science
Workflow 03
Diagnostic and Assay Strategy
Evaluate assay options and testing pathways needed to support biomarker-driven programs, including CDx, IVD, vendor landscape, and implementation risks.
Includes
- Assay landscape review
- Vendor-agnostic test recommendations
- Cutoff and sample type considerations
- Assay readiness and implementation risk
Example outputs
- Assay recommendation summary
- Diagnostic pathway considerations
- Vendor and test landscape
- Cutoff and sample-type risk flags
hub
Workflow 04
Biomarker-Based Evidence Generation
Plan evidence packages that support clinical utility, medical value, diagnostic adoption, stakeholder confidence, and value communication.
Includes
- Evidence gap analysis
- Clinical utility strategy
- RWE opportunity assessment
- Medical and scientific narrative support
Example outputs
- Evidence generation roadmap
- Clinical utility framework
- Value narrative
- Stakeholder-ready summary